Form 4: Denali Therapeutics Director Vicki L. Sato Reports Stock Sale
SEC Form 4 Filing
Director Vicki L. Sato reported selling shares of Denali Therapeutics Inc. under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 3, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 2,980 shares of common stock at a weighted average price of $24.99, with prices ranging from $24.37 to $25.32 per share.
- An additional 100 shares were sold at $25.37 per share on the same day.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 21, 2024.
- Following the transactions, Sato directly owns 116,176 shares of Denali Therapeutics Inc., which includes 5,967 unvested RSUs.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan, which is a common and legal practice.
Industry Context
Sales by company insiders are a common occurrence and are often viewed in the context of pre-arranged trading plans to avoid accusations of trading on material non-public information. It's important to consider the size of the sale relative to the insider's holdings and the overall trading volume of the stock.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although sales under 10b5-1 plans are usually anticipated by the market.
Key Dates
| Date | Description |
|---|---|
| 03/21/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 09/03/2024 | Date of stock sale transactions |
| 09/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.